6 news items
Bio-Path Holdings Reports First Quarter 2024 Financial Results
BPTH
15 May 24
will provide meaningful protection of our drug candidates, the impact, risks and uncertainties related to global pandemics, including the COVID-19 pandemic
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BPTH
19 Apr 24
or that any issued patents will provide meaningful protection of our drug candidates, the impact, risks and uncertainties related to global pandemics, including
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BPTH
18 Apr 24
meaningful protection of our drug candidates, the impact, risks and uncertainties related to global pandemics, including the COVID-19 pandemic, and actions
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
BPTH
18 Apr 24
or that any issued patents will provide meaningful protection of our drug candidates, the impact, risks and uncertainties related to global pandemics
Bio-Path Holdings Provides 2024 Clinical and Operational Update
BPTH
2 Apr 24
of our drug candidates, the impact, risks and uncertainties related to global pandemics, including the COVID-19 pandemic, and actions taken
5cwngg3 flz8
BPTH
8 Mar 24
to global pandemics, including the COVID-19 pandemic, and actions taken by governmental authorities or others in connection therewith, and such other
- Prev
- 1
- Next